news
03 February 2021
Da Volterra Receives first Authorizations from Regulatory Authorities in EU Countries to Initiate its Phase 3 Clinical Trial Evaluating the Microbiome Protector DAV132 in Patients with Hematologic Malignancies
• World-first phase 3 study of a microbiome protector • Da Volterra becomes a pioneering late-stage clinical company…